Core Viewpoint - The National Healthcare Security Administration (NHSA) has recently disclosed multiple cases of pharmaceutical bribery, highlighting the need for stricter oversight and accountability in the healthcare sector [1][5]. Group 1: Bribery Cases - The NHSA reported several bribery cases, including the case of Liu Mouhong, the director of the pharmacy department at Shuangshan Hospital in Anshan, and others involving significant sums of money [1][4]. - In the case involving a Shanghai trading company, a total of RMB 662.55 million was paid as kickbacks to Wu Mouli, a director at Hebei Medical University Second Hospital, with cash delivered in brown paper bags [2][3]. - Huang Mouyun, responsible for sales of a traditional Chinese medicine product, paid kickbacks totaling RMB 163.63 million to 15 doctors at a hospital to boost sales [4]. Group 2: Regulatory Actions - The NHSA plans to implement a credit rating system for companies involved in bribery and illegal sales practices, which will include restrictions on their ability to participate in public procurement and distribution [5][6]. - The NHSA aims to guide local healthcare authorities in conducting credit ratings and ensuring that companies take corrective actions to address their misconduct [6].

Core Insights - The National Healthcare Security Administration (NHSA) has recently exposed multiple corruption and illegal cases involving various pharmaceutical companies, including Medtronic, Qianhong Pharmaceutical, and Dezhan Health, highlighting systemic issues in the medical procurement process [1][4]. Group 1: Corruption Cases - Medtronic's agents were found to have bribed hospital officials to promote the sale of stents and balloons, with kickbacks of 5,000 RMB per stent and varying amounts for balloons based on their price [2][3]. - The total amount of bribes received by a hospital vice president from Medtronic's agents was reported to be over 6.74 million RMB from 2014 to 2018 [2]. - In a separate case, Qianhong Pharmaceutical and Dezhan Health were implicated in bribery involving hospital procurement officials, with Qianhong's agent providing 41,000 RMB in kickbacks [4]. Group 2: Regulatory Response - The NHSA has established a credit evaluation system for pricing and procurement to address the issues of inflated drug prices and corruption, aiming to protect patients and healthcare funds [5]. - The NHSA plans to guide local healthcare authorities in implementing trust ratings for companies involved in bribery and misconduct, enforcing measures to ensure compliance and safeguard healthcare funds [5].